| Bioactivity | TP-10 is a selective PDE10A inhibitor with an IC50 value of 0.8 nM. TP-10 shows an antioxidant activity with IC50s of 31.72 and 16.04 μg/ml for DPPH and CUPRAC, respectively. TP-10 can be used for the research of neuropathy[1][2][3]. | ||||||||||||
| Target | IC50: 0.8 nM (PDE10A), 31.72 μg/mL (DPPH), 16.04 μg/mL (CUPRAC) | ||||||||||||
| Invitro | TP-10 (10 μg /mL; 24 h) affects total reactive oxygen species in human brain-derived cells (U-87 MG)[3]. Cell Viability Assay[3] Cell Line: | ||||||||||||
| In Vivo | TP-10 (0.1-10 mg/kg; i.h. once) shows an effect on cyclic nucleotides[2]. Animal Model: | ||||||||||||
| Name | TP-10 | ||||||||||||
| CAS | 898563-00-3 | ||||||||||||
| Formula | C26H19F3N4O | ||||||||||||
| Molar Mass | 460.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hamaguchi W, et al. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors. Chem Pharm Bull (Tokyo). 2014;62(12):1200-1213. [2]. Schmidt CJ, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008 May;325(2):681-90. [3]. Kaproń B, et al. 1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy. J Enzyme Inhib Med Chem. 2020 Dec;35(1):993-1002. |